191 results
Keyword epoetin Remove keyword
-
List item
Press release: EMEA recommends a new warning for epoetins for their use in cancer patients
CHMP, Last updated: 26/06/2008recommends a new warning for epoetins for their use in cancer patients … product information for epoetin-containing medicines with a new warning … patients suffering cancer. Epoetin-containing medicines are indicated in … -
List item
News: Public Statement: Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease
CHMP, Last updated: 23/10/2007recently reviewed the safety of epoetins. These medicines are used … who have been treated with epoetins. In addition, the results … treatment of anaemia with epoetins in patients with chronic … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018
CHMP, Last updated: 27/07/2018Epoetin alfa Hexal, Kalydeco, Mekinist … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,23-26 June 2008
CHMP, Last updated: 26/06/2008QUESTIONS AND ANSWERS ON EPOETINS AND THE RISK OF TUMOUR … has reviewed the safety of epoetins used in cancer patients … prescribing information for all epoetin-containing medicines stating that blood … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 July 2012
CHMP, Last updated: 20/07/2012methoxy polyethylene glycol-epoetin beta, peginterferon alfa-2a … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)20-23 June 2011
CHMP, Last updated: 24/06/2011neuropathy. Retacrit (epoetin zeta), from Hospira UK Ltd … epoetin zeta), from Hospira UK Ltd … -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 September 2018
European Medicines Agency, London, UK, from 17/09/2018 to 20/09/2018, Last updated: 31/10/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 July 2017
European Medicines Agency, London, UK, from 17/07/2017 to 20/07/2017, Last updated: 06/01/2014